Compare · AZN vs KVSA
AZN vs KVSA
Side-by-side comparison of AstraZeneca PLC (AZN) and Khosla Ventures Acquisition Co. (KVSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and KVSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $257.64B, about 654.6x KVSA ($393.6M).
- AZN has hit the wire 30 times in the past 4 weeks while KVSA has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 0 for KVSA).
- Company
- AstraZeneca PLC
- Khosla Ventures Acquisition Co.
- Price
- -
- -
- Market cap
- $257.64B
- $393.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 30
- 0
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Khosla Ventures Acquisition Co.
Khosla Ventures Acquisition Co. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2021 and is based in Menlo Park, California.
Latest AZN
- Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca upgraded by Deutsche Bank
- SEC Form 6-K filed by AstraZeneca PLC
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
- Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- Officer Sharma Mani bought $3,249 worth of Ordinary Shares (20 units at $160.57) and was granted 1 units of Ordinary Shares, increasing direct ownership by 0.11% to 19,289 units (SEC Form 4)
Latest KVSA
- SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)
- SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)
- SEC Form 15-12G filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Reports Redemption Of Public Shares And Subsequent Dissolution
- Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution
- OpenAI Investor Vinod Khosla Works 80 Hours A Week, Will Use Peter Thiel's Anti-Aging Methods If They Work
- SEC Form 10-Q filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Co. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing